Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B

Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis

Published
16 April 2014
By
Liz Highleyman
Hepatitis delta virus co-infection increases risk of poor liver-related outcomes for people living with HIV

Co-infection with hepatitis delta virus (HDV) is a major risk factor for hepatic decompensation and liver-related death in people living with HIV, Spanish investigators report in the online

Published
28 March 2014
By
Michael Carter
Booster Shots Needed for People with HIV?

Previous research indicates people with HIV have a reduced immune response to most vaccines, but how does immune response hold up over time—and what are the implications for re-vaccinating with “booster shots”?

Published
26 January 2014
From
BETA blog
China's Struggle With Hepatitis B Discrimination

Job applicants and students are regularly turned down on the basis of the disease. Now, some are fighting back.

Published
04 December 2013
From
The Atlantic
Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who

Published
29 November 2013
By
Liz Highleyman
Hepatitis B treatment with entecavir or tenofovir lowers, but does not eliminate, liver cancer risk

Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma, according to findings presented this week at The Liver Meeting

Published
06 November 2013
By
Liz Highleyman
Men-only hepatitis B mutation explains higher cancer rates

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer. Although some women do progress to cirrhosis and liver cancer, the mutation is absent in HBV in women. The research is published ahead of print in the Journal of Clinical Microbiology.

Published
18 October 2013
From
Eurekalert Inf Dis
Vaccination campaign doubles HBV mutations

A universal infant vaccination campaign in China has led the hepatitis B virus to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

Published
08 October 2013
From
Eurekalert Medicine & Health
Liver cancer often diagnosed late with poor survival in people with HIV

Hepatocellular carcinoma is frequently diagnosed at an advanced stage in HIV-positive people with hepatitis B or C co-infection, contributing to a high mortality rate that has changed little

Published
04 October 2013
By
Liz Highleyman
FDA Warns of Hepatitis B Reactivation Risk with Immune-suppressing Cancer Drugs

The U.S. Food and Drug Administration (FDA) announced this week that it has approved labeling changes for 2 monoclonal antibody cancer drugs, ofatumumab (Arzerra) and rituximab (Rituxan), adding a stronger "black box" warning that they may cause hepatitis B virus (HBV) reactivation.

Published
30 September 2013
From
HIVandhepatitis.com
← First12345...10Next →

Filter by country